TW200602335A - Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof - Google Patents

Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof

Info

Publication number
TW200602335A
TW200602335A TW094109952A TW94109952A TW200602335A TW 200602335 A TW200602335 A TW 200602335A TW 094109952 A TW094109952 A TW 094109952A TW 94109952 A TW94109952 A TW 94109952A TW 200602335 A TW200602335 A TW 200602335A
Authority
TW
Taiwan
Prior art keywords
hydrogen
medicinal
naphthalene derivative
same
composition containing
Prior art date
Application number
TW094109952A
Other languages
Chinese (zh)
Inventor
Hideki Fujikura
Nobuhiko Fushimi
Masayuki Isaji
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of TW200602335A publication Critical patent/TW200602335A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Abstract

A naphthalene derivative represented by the following general formula (I) or a pharmacologically acceptable salt of the derivative. They have human SGLT inhibitory activity and are useful as a preventive or therapeutic agent for diseases attributable to hyperglycemia, such as diabetes and obesity. In the chemical structural formula, R1 to R6 each is hydrogen, OH, NH2, etc.; R7 and R8 each is hydrogen, OH, halogen, etc.; Q is alkyline, alkylene, etc.; ring A is aryl, heteroaryl, etc.; and G is a group represented by the following general formula (G-1) or (G-2); E1 is hydrogen, fluorine or OH; E2 is hydrogen, fluorine or methyl group.
TW094109952A 2004-03-31 2005-03-30 Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof TW200602335A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004101895 2004-03-31

Publications (1)

Publication Number Publication Date
TW200602335A true TW200602335A (en) 2006-01-16

Family

ID=35063697

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094109952A TW200602335A (en) 2004-03-31 2005-03-30 Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof

Country Status (3)

Country Link
JP (1) JPWO2005095373A1 (en)
TW (1) TW200602335A (en)
WO (1) WO2005095373A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
BRPI0918841B8 (en) 2008-08-28 2021-05-25 Pfizer dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives, their crystals, pharmaceutical compositions and uses
SI2496583T1 (en) 2009-11-02 2015-02-27 Pfizer Inc. Dioxa-bicycloš3.2.1ćoctane-2,3,4-triol derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
JP4456768B2 (en) * 2000-02-02 2010-04-28 壽製薬株式会社 Drug containing C-glycoside
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
TWI254635B (en) * 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof

Also Published As

Publication number Publication date
WO2005095373A1 (en) 2005-10-13
JPWO2005095373A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
NO20064412L (en) Condensed heterocycle derivative, medical composition containing the same and medical use thereof
WO2008117269A3 (en) Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
TW200745111A (en) New compounds
TW200635924A (en) Chemical compounds
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
UY28922A1 (en) RECEIVER CB1 LINKS USEFUL IN THE TREATMENT OF PAIN AND / OR OTHER SYMPTOMS OR RELATED DISEASES; PHARMACEUTICAL COMPOUNDS AND THEIR PREPARATION.
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
WO2003064404A1 (en) 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
NO20051962L (en) Phenethanolamine derivatives for the treatment of respiratory diseases
TW200621259A (en) Chemical compounds
TW200640908A (en) Chemical compounds
EA021275B9 (en) Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease
MX2007008614A (en) Peptides with neuropeptide-2 receptor (y2r) agonist activity.
NO20082445L (en) Neuropeptide-2 receptor agonists
TW200630352A (en) Chemical compounds
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
MX2009010165A (en) New imidazo[ 4,5-b]pyridine-7-carboxamides 704.
TW200634001A (en) Novel compounds
MXPA05013856A (en) 5ht2c receptor agonists for the treatment of diabetes and obesity.
TW200800984A (en) New compounds
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
TW200602335A (en) Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
TW200616635A (en) Novel compounds